260 related articles for article (PubMed ID: 9617321)
1. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
2. Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59).
Shibata J; Toko T; Saito H; Lykkesfeldt AE; Fujioka A; Sato K; Hashimoto A; Wierzba K; Yamada Y
Cancer Chemother Pharmacol; 2000; 45(2):133-41. PubMed ID: 10663628
[TBL] [Abstract][Full Text] [Related]
3. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
4. Effects of tamoxifen and the derivative (TAT) on cell cycle of MCF-7 in vitro.
Tominaga T; Yoshida Y; Matsumoto A; Hayashi K; Kosaki G
Anticancer Res; 1993; 13(3):661-5. PubMed ID: 8317894
[TBL] [Abstract][Full Text] [Related]
5. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
Toko T; Shibata J; Nukatsuka M; Yamada Y
Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
[TBL] [Abstract][Full Text] [Related]
6. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
ter Haar E; Day BW
Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
[TBL] [Abstract][Full Text] [Related]
7. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
8. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
[TBL] [Abstract][Full Text] [Related]
9. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors.
Toko T; Sugimoto Y; Matsuo K; Yamasaki R; Takeda S; Wierzba K; Asao T; Yamada Y
Eur J Cancer; 1990 Mar; 26(3):397-404. PubMed ID: 2141500
[TBL] [Abstract][Full Text] [Related]
10. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
11. [Antitumor activity of a new antiestrogenic drug, toremifene (NK622) against human breast cancer xenografts in nude mice].
Kuroiwa S; Koyama M; Watanabe N; Ekimoto H; Ohnishi Y; Saito M; Maruo K; Inaba M; Tashiro T; Yamori T
Gan To Kagaku Ryoho; 1993 Apr; 20(5):617-23. PubMed ID: 8470919
[TBL] [Abstract][Full Text] [Related]
12. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice.
Zhang L; Kharbanda S; Chen D; Bullocks J; Miller DL; Ding IY; Hanfelt J; McLeskey SW; Kern FG
Oncogene; 1997 Oct; 15(17):2093-108. PubMed ID: 9366526
[TBL] [Abstract][Full Text] [Related]
13. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice.
McLeskey SW; Kurebayashi J; Honig SF; Zwiebel J; Lippman ME; Dickson RB; Kern FG
Cancer Res; 1993 May; 53(9):2168-77. PubMed ID: 8481920
[TBL] [Abstract][Full Text] [Related]
15. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
16. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
[TBL] [Abstract][Full Text] [Related]
17. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
Leclercq G; Devleeschouwer N; Heuson JC
J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
[TBL] [Abstract][Full Text] [Related]
18. [Hormone independent murine carcinoma BX-1 spontaneously arising from nude mouse bearing Br-10, a hormone dependent human breast carcinoma strain].
Kubota T; Oka S; Utsumi T; Enomoto K; Ishibiki K; Abe O; Koh J; Shiina E; Asanuma F; Yamada Y
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2081-6. PubMed ID: 3395136
[TBL] [Abstract][Full Text] [Related]
19. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
20. [Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)].
Nomura Y; Nakajima M; Tominaga T; Abe O
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1045-63. PubMed ID: 9644320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
